New drug added to stem cell transplant shows promise for tough blood cancer
NCT ID NCT04680468
Summary
This study is testing if adding a targeted drug called belantamab mafodotin before and after a stem cell transplant helps people with multiple myeloma. The goal is to see if this combination is safe and more effective at keeping the cancer in check compared to past treatments. It will involve about 41 adults who have recently started treatment and are eligible for a transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.